Highest-materiality recent filing
Incyte Q1 revenue $1.27B (+21% YoY), Non-GAAP EPS $1.81 beats prior $1.16; pipeline expands
Total net sales $1.10B (+20% YoY); Jakafi $758M (+7%), Opzelura $143M (+20%), Hem/Onc $204M (+116%).
FDA issues Complete Response Letter for Incyte's Zynyz in NSCLC due to facility inspection findings
FDA CRL for Zynyz (retifanlimab) sBLA for metastatic NSCLC with platinum chemo, citing Catalent Indiana inspection findings.
Incyte Q4 total revenue $1.51B (+28% YoY); FY 2025 net product revenue beat guidance
Q4 total revenue $1.51B (+28% YoY); net product revenue $1.22B (+20%). FY 2025 net product revenue $4.35B, above $4.23-4.32B guidance.
Incyte Q3 revenue $1.37B (+20% YoY); raises FY 2025 product revenue guidance to $4.23-4.32B
GAAP diluted EPS $2.11 vs $0.54 YoY; Non-GAAP diluted EPS $2.26 vs $1.07.
Incyte CFO Christiana Stamoulis to step down effective September 16, 2025
CFO Christiana Stamoulis notified Incyte of her resignation to pursue another opportunity.
Incyte Q2 2025 revenue up 16% to $1.216B; raised Jakafi and oncology guidance
Total revenues $1.216B (+16% YoY); net product rev $1.059B (+17% YoY). GAAP EPS $2.04 diluted, vs $(2.04) loss a year ago.
Incyte appoints William J. Meury as President and CEO; Hervé Hoppenot retires
Hervé Hoppenot retired as President & CEO effective June 26, 2025; will serve as special advisor for up to one year.
Incyte settles JAKAFI royalty dispute with Novartis; pays $280M vs $537M accrued
Settlement resolves litigation over royalty duration under 2009 Collaboration and License Agreement.
Incyte Q1 2025 revenues up 20% to $1.05B; Jakafi guidance raised
Total revenues $1,053M (+20% YoY); product rev $922M (+26%); GAAP diluted EPS $0.80; Non-GAAP $1.16.
Incyte Q4 2024 revenue $1.18B (+16% YoY), guides 2025 Jakafi $2.93-2.98B, Opzelura $630-670M
Q4 total revenues $1.18B (+16% YoY); full year $4.24B (+15%). GAAP diluted EPS $1.02 (Q4), $0.15 (FY); Non-GAAP $1.43 (Q4), $1.08 (FY).
Incyte Q3 2024 revenues up 24% to $1.14B; Jakafi guidance raised
Total revenues $1.138B (+24% YoY); Jakafi net revenue $741M (+16%); Opzelura $139M (+52%).
Q2 net loss $445M; revs up 9% to $1.04B; Jakafi guidance raised; $2B buyback completed
Total revenues $1,044M (+9% YoY); Jakafi $706M (+3%), Opzelura $122M (+52%).
Incyte commences $1.672B Dutch auction tender offer, agrees to buy $328M from Baker Entities
Incyte commences modified Dutch auction tender offer to repurchase up to $1.672 billion of common stock at $52-$60 per share.
Incyte Q1 revenues $881M (+9% YoY), GAAP EPS $0.75; to acquire Escient for $750M
Revenue $881M (+9% YoY); GAAP net income $169.5M, diluted EPS $0.75.
On January 6, 2025, Barry P. Flannelly, Executive Vice President, General Manager, North America of Incyte Corporation (the “Company”), announced his retirement from the Company and stepped down from that role on that date, effective with the commencement of employment of his successor.
Max materiality 0.90 · Median 0.75 · Most common event earnings